Table 3.
TEAEs (All-Causality) in Greater Than or Equal to 20% Patients (in Either Cohort, Any Grade)
| MedDRA Preferred Term | Cohort A KRAS-mt NSCLC (N = 25), n (%) |
Cohort B Squamous NSCLC (N = 25), n (%) |
||
|---|---|---|---|---|
| Any Grade | Grade ≥3 | Any Grade | Grade ≥3 | |
| Patients with ≥1 TEAE | 25 (100) | 20 (80) | 25 (100) | 19 (76) |
| Diarrhea | 15 (60) | 3 (12) | 16 (64) | 0 |
| Vomiting | 10 (40) | 2 (8) | 5 (20) | 1 (4) |
| Abdominal pain | 10 (40) | 1 (4) | 2 (8) | 0 |
| Nausea | 10 (40) | 2 (8) | 8 (32) | 0 |
| Decreased appetite | 9 (36) | 1 (4) | 10 (40) | 0 |
| Fatigue | 9 (36) | 0 | 15 (60) | 2 (8) |
| Pneumonitis | 8 (32) | 3 (12) | 1 (4) | 0 |
| AST increased | 8 (32) | 3 (12) | 1 (4) | 0 |
| Dyspnea | 8 (32) | 0 | 11 (44) | 3 (12) |
| ALT increased | 7 (28) | 6 (24) | 1 (4) | 0 |
| Neutropenia | 6 (24) | 3 (12) | 3 (12) | 0 |
| Lung infection | 6 (24) | 2 (8) | 4 (16) | 3 (12) |
| Anemia | 6 (24) | 1 (4) | 5 (20) | 0 |
| Leukopenia | 5 (20) | 1 (4) | 1 (4) | 0 |
| Muscular weakness | 5 (20) | 1 (4) | 4 (16) | 1 (4) |
| Pruritus | 5 (20) | 1 (4) | 8 (32) | 0 |
| Dizziness | 5 (20) | 0 | 0 | 0 |
| Pain | 5 (20) | 0 | 0 | 0 |
| Pain in extremity | 5 (20) | 0 | 0 | 0 |
| Cough | 4 (16) | 0 | 9 (36) | 0 |
| Thrombocytopenia | 4 (16) | 0 | 8 (32) | 3 (12) |
| Headache | 4 (16) | 0 | 5 (20) | 0 |
| Hypophosphatemia | 1 (4) | 1 (4) | 6 (24) | 3 (12) |
| Myalgia | 1 (4) | 0 | 5 (20) | 2 (8) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; KRAS-mt, KRAS-mutant; MedDRA, Medical Dictionary for Regulatory Activities; n, number of subjects in the specified category; N, number of subjects in safety population; TEAE, treatment-emergent adverse event.